Anti-phospho-Epidermal Growth Factor Receptor (pTyr⁸⁴⁵) antibody produced in rabbit

Immunogen

synthetic phosphopeptide derived from the region of EGFR that contains tyrosine 845.

General description

The members of epidermal growth factor receptor (EGF R) or the ErbB receptor family have been identified as useful biomarkers and targets for cancer therapy. The EGFR family includes four receptor tyrosine kinases, EGF R (ErbB1), ErbB2 (neu), ErbB3, and ErbB4. EGF R binds EGF and induces tyrosine phosphorylation leading to proliferation of cells. ^1,2 EGF R is present on many cell types of epithelial and mesenchymal lineages. EGF R is capable of binding transforming growth factor-α and heparin-binding EGF in addition to EGF. ^3,4 There are numerous effector molecule activated by EGF R that result in a variety of biological processes such as morphogenesis, cell motility, apoptosis, differentiation and organ repair and maintenance. Deregulation of EGF R signaling is implicated in progression of a wide variety of tumors, invasion and metastasis^1,4 Interaction of EGF R with c-Src kinase contributes in aggressiveness of human tumors. The phosphorylation of EGF R at Tyr⁸⁴⁵ and Tyr¹¹⁰¹ is mediated by c-Src and helps in the association of c-Src with EGF R⁵
Anti-phospho-EGFR [pTyr⁸⁴⁵] specifically recognizes EGFR phosphorylated at tyrosine 845 (170 kDa). The antibody detects human, mouse and rat EGFR [pTyr⁸⁴⁵].

Physical form

Solution in Dulbecco′s phosphate buffered saline (without Mg²⁺ and Ca²⁺), pH 7.3, with 50% glycerol, 1.0 mg/ml BSA (IgG and protease free) and 0.05% sodium azide.

Application

Anti-phospho-EGFR [pTyr⁸⁴⁵] may be used for immunoblotting at a working dilution of 1:1000 in human A431 cells treated with EGF. The antibody is suitable for immunocytochemistry.

Features and Benefits

Antibody Bioguarantee
Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.